Royalty Pharma Plc stock is traded at $67.30, with a volume of 4,812,978. It is down -0.40% in the last 24 hours and up +19.24% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Previous Close:
$67.57
Open:
$66.52
24h Volume:
4,812,978
Relative Volume:
1.34
Market Cap:
$29.97B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
35.25
EPS:
$1.91
Net Cash Flow:
$574.14M
1W Performance:
+0.18%
1M Performance:
+19.24%
6M Performance:
+32.69%
1Y Performance:
+65.03%
1-Day Range:
$66.52$68.15
1-Week Range:
$64.84$69.77
52-Week Range:
$37.31$69.77
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma PlcSector
HealthcareIndustry
BiotechnologyPhone
(212) 883-0200Address
110 EAST 59TH STREET, NEW YORK, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS